Christine Saunders;Aurelio Galli;Kevin Niswender;Heinrich J.G. Matthies;Sabrina Robertson;Kevin Erreger;Adeola Davis
发明人:
Aurelio Galli,Kevin Erreger,Kevin Niswender,Sabrina Robertson,Christine Saunders,Heinrich J.G. Matthies,Adeola Davis
申请号：
US13134577
公开号：
US20120021979A1
申请日:
2011.06.10
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention involves the use of GLP-1 and its analogs or GLP-1 receptor agonists to modulate dopamine transporter signaling. The implications of this ability include the use of MT-1 and its analogs or GLP-1 receptor agonists, such as exendin-4, to blunt behavioral response to addictive drugs, to decrease drug dependence, to prevent drug abuse relapse, and to treat brain disorders such as neuropsychiatric disorders including ADHD. The present invention also involves the use of GLP-1 and its analogs or GLP-1 receptor agonists to activate GLP-1R in penile tissue, such as for the treatment of erectile dysfunction either as a monotherapy or in combinations with other treatments, such as PDE 5 inhibitors.
